Vaccine Therapy in Treating Young Patients Who Are Undergoing Surgery for Malignant Glioma

Inclusion Criteria: * Histologically confirmed\* WHO grade III or IV malignant glioma of 1 of the following subtypes: * Anaplastic astrocytoma * Anaplastic oligodendroglioma * Glioblastoma multiforme NOTE: \*Must be confirmed after surgery * Newly diagnosed OR recurrent disease * Bidimensionally measurable disease by contrast-enhancing pre-operative MRI * Surgically accessible tumor for which surgical resection is indicated at the time of initial pre-operative evaluation * Must have undergone standard surgery\* AND either radiotherapy\* or chemoradiotherapy\* * Objective evidence of disease by contrast-enhanced brain MRI after completion of standard therapy NOTE: \*Completed after study entry but before assignment to study treatment cohorts * Age 1 to 18 * Performance status Karnofsky 60-100% * Hematopoietic * Hemoglobin ≥ 10 g/dL * Absolute granulocyte count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Hepatic * SGPT and SGOT ≤ 2 times normal * Alkaline phosphatase ≤ 2 times normal * Bilirubin ≤ 1.5 mg/dL * Hepatitis B and C negative * Renal * BUN ≤ 1.5 times normal OR * Creatinine ≤ 1.5 times normal * Immunologic * HIV negative * Syphilis negative * At least 2 weeks since prior radiotherapy and recovered * Negative pregnancy test * Fertile patients must use effective contraception * More than 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered * No chemotherapy during and for 4 weeks\* after the final dose of study vaccine * No corticosteroids for at least 10 days before leukapheresis * No concurrent corticosteroids * More than 72 hours since prior systemic antibiotics * No antihistamines for 5 days before and for 5 days after administration of study vaccine Exclusion Criteria: * history of immunodeficiency or autoimmune disease that may be exacerbated by immunotherapy, including any of the following: * Rheumatoid arthritis * Systemic lupus erythematosus * Vasculitis * Polymyositis * Dermatomyositis * Scleroderma * Multiple sclerosis * Juvenile-onset insulin-dependent diabetes * active infection * fever * allergy to study reagents * pregnant or nursing * other malignancy within the past 5 years except adequately treated basal cell or squamous cell skin cancer, localized prostate cancer, or carcinoma in situ of the cervix * unstable or severe medical or psychiatric condition, as determined by the investigator * underlying condition that would preclude study participation * concurrent radiotherapy * prior organ allograft * concurrent strong painkillers * other concurrent immune-suppressing medications * other concurrent investigational agents * other adjuvant treatment for 4 weeks\* after the final dose of study vaccine NOTE: \*Unless there is evidence of tumor progression necessitating additional clinically-indicated treatment; patients requiring treatment due to tumor progression are removed from the study